focus -WSS

focus

author：entertainment 2025-09-28 02:32:59 - browse：6351

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Why hospitals are withdrawing from US News rankings

leisure time

WSS

A public scorecard can help hold safety

Google and Epic fight stronger regulation of AI in health care

Cosmetics set for new safety regulation. Why the industry is on board

Sanofi seeks simpler, safer CRISPR sickle cell cure

The Pandemic Treaty must support building strong health systems

ASCO: Palliative care found as helpful given virtually as in person

knowledge

focus

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

At Orexo, a ‘turning point’ for everything but digital health

Jerome Adams on the need for new antivirals for Covid

NIH documents show early flaws of $1.6 billion long Covid program

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Wegovy in the brain & pivotal Alzheimer's data

New air purifier tech could be key to improving indoor air quality

AI can’t replace a physician’s gut feeling

Walensky prepares to leave CDC — and Congress — behind

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

leisure time

NIH documents show early flaws of $1.6 billion long Covid program

At ASCO, AstraZeneca reports strong data for breast cancer drug

Custom gene therapy hints at new path for rare disease treatments

FDA approves RSV monoclonal antibody for infants, toddlers

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Ionis drug prevents swelling attacks due to hereditary angioedema

focus

leisure time

focus

Wikipedia